Sonpavde GP - Search Results

1

A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial.

Satkunasivam R, Lim K, Teh BS, Guzman J, Zhang J, Farach A, Chen SH, Wallis CJ, Efstathiou E, Esnaola NF, Sonpavde GP. Satkunasivam R, et al. Among authors: sonpavde gp. Future Oncol. 2022 Aug;18(25):2771-2781. doi: 10.2217/fon-2022-0380. Epub 2022 Jun 15. Future Oncol. 2022. PMID: 35703113

2

Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder.

Ziari M, Sonpavde G, Shen S, Teh BS, Shu T, Lerner SP. Ziari M, et al. J Clin Oncol. 2005 Jul 1;23(19):4458-9. doi: 10.1200/JCO.2005.06.060. J Clin Oncol. 2005. PMID: 15994155 No abstract available.

3

Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult.

Ziari M, Sonpavde G, Shen S, Zhai J, Teh BS, Lerner SP. Ziari M, et al. J Clin Oncol. 2005 Jul 1;23(19):4459-60. doi: 10.1200/JCO.2005.06.046. J Clin Oncol. 2005. PMID: 15994156 No abstract available.

4

Vaccine therapy for prostate cancer.

Sonpavde G, Spencer DM, Slawin KM. Sonpavde G, et al. Urol Oncol. 2007 Nov-Dec;25(6):451-9. doi: 10.1016/j.urolonc.2007.01.010. Urol Oncol. 2007. PMID: 18047951 Review.

5

Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.

Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Gartrell BA, et al. Eur Urol. 2015 Nov;68(5):850-8. doi: 10.1016/j.eururo.2015.06.039. Epub 2015 Jul 4. Eur Urol. 2015. PMID: 26153564 Review.

6

Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Einstein DJ, Sonpavde G. Einstein DJ, et al. Curr Treat Options Oncol. 2019 Feb 11;20(2):12. doi: 10.1007/s11864-019-0609-6. Curr Treat Options Oncol. 2019. PMID: 30741358 Review.

7

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.

Sonpavde G, Necchi A, Gupta S, Steinberg GD, Gschwend JE, Van Der Heijden MS, Garzon N, Ibrahim M, Raybold B, Liaw D, Rutstein M, Galsky MD. Sonpavde G, et al. Future Oncol. 2020 Jan;16(2):4359-4368. doi: 10.2217/fon-2019-0611. Epub 2019 Dec 11. Future Oncol. 2020. PMID: 31823654 Clinical Trial.

8

Neoadjuvant therapy for muscle-invasive bladder cancer.

Jain RK, Sonpavde G. Jain RK, et al. Expert Rev Anticancer Ther. 2020 Jul;20(7):603-614. doi: 10.1080/14737140.2020.1784011. Epub 2020 Jun 30. Expert Rev Anticancer Ther. 2020. PMID: 32546025 Review.

9

Sonpavde GP, Grivas P, Lin Y, Hennessy D, Hunt JD. Sonpavde GP, et al. Future Oncol. 2021 Jul;17(19):2545-2558. doi: 10.2217/fon-2020-1222. Epub 2021 Mar 30. Future Oncol. 2021. PMID: 33783228

10

Utilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: An analysis of the national cancer database.

Dursun F, Mackay A, Guzman JCA, Wenker E, Klaassen Z, O'Malley P, Bhindi B, Perez CO, Xu J, Roh T, Sonpavde G, Wallis CJD, Satkunasivam R. Dursun F, et al. Urol Oncol. 2022 Feb;40(2):61.e21-61.e28. doi: 10.1016/j.urolonc.2021.07.015. Epub 2021 Aug 1. Urol Oncol. 2022. PMID: 34348861

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

482 results

Search Page